Company intelligence / Profile preview

SLA Pharma

Ownership: Private
Development stage: Other

Overview

SLA Pharma has demonstrated clinically and statistically significant results in a Phase 2 trial for opioid-induced constipation with Nalcol™ (oral naloxone), showing dose-related increases in spontaneous bowel movements without impacting pain or causing opioid withdrawal symptoms. The company’s pipeline includes late-stage clinical programs targeting gastrointestinal and rare disorders, including fecal incontinence, anal fissure, Crohn's disease symptoms, and familial adenomatous polyposis

Therapeutic areas: Gastroenterology
Modalities: Small molecule drugChemical (for some programs)
Industry: Biotech

Drug pipeline

4 assets

EPAspire

3 more assets in the full pipeline.

Request access →

Partnerships

SLA Pharma forms partnerships with other pharmaceutical companies for sales and marketing expertise to commercialize their products; specific partners are not named publicly as of the latest available data

Beyond the preview

Go deeper on SLA Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SLA Pharma.

Explore the full profile